HeimGSK • NYSE
add
GSK plc
40,07 $
Fyrir opnun:(0,025%)-0,0100
40,06 $
Lokað: 21. ágú., 05:34:36 GMT-4 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
39,62 $
Dagbil
39,81 $ - 40,55 $
Árabil
31,72 $ - 44,67 $
Markaðsvirði
80,73 ma. USD
Meðalmagn
5,14 m.
V/H-hlutf.
17,92
A/V-hlutfall
4,11%
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 7,99 ma. | 1,29% |
Rekstrarkostnaður | 3,39 ma. | -3,34% |
Nettótekjur | 1,44 ma. | 23,02% |
Hagnaðarhlutfall | 18,07 | 21,44% |
Hagnaður á hvern hlut | 1,24 | 185,82% |
EBITDA | 3,60 ma. | 21,53% |
Virkt skatthlutfall | 12,77% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,62 ma. | 21,32% |
Heildareignir | 59,26 ma. | 2,05% |
Heildarskuldir | 44,90 ma. | 1,37% |
Eigið fé alls | 14,35 ma. | — |
Útistandandi hlutabréf | 4,05 ma. | — |
Eiginfjárgengi | 10,85 | — |
Arðsemi eigna | 10,16% | — |
Ávöxtun eigin fjár | 19,10% | — |
Peningaflæði
Breyting á handbæru fé
| (GBP) | jún. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 1,44 ma. | 23,02% |
Handbært fé frá rekstri | 2,10 ma. | 88,32% |
Reiðufé frá fjárfestingum | -625,00 m. | -181,17% |
Reiðufé frá fjármögnun | -2,37 ma. | -49,75% |
Breyting á handbæru fé | -927,00 m. | -418,56% |
Frjálst peningaflæði | 935,12 m. | 51,50% |
Um
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine. Wikipedia
Framkvæmdastjóri
Stofnsett
27. des. 2000
Vefsvæði
Starfsfólk
68.629
